Piper Sandler keeps Buy on Amgen stock; EUR 398.23, down 0.41%
Published on 11/20/2026 at 08:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst support meets pipeline focus
- Piper Sandler maintained its Buy rating and a USD 457 price target for Amgen.
- Amgen's growth portfolio includes Repatha, UPLIZNA and IMDELLTRA.
- The company's newer products are helping offset pressure on established franchises.
Amgen stock traded at EUR 398.23 on Lang & Schwarz at 08:38 CET on Friday, November 20, 2026, 0.41 percent below the Xetra close of Thursday, November 19, at EUR 399.85.
Piper Sandler keeps a bullish stance
Piper Sandler analyst David Amsellem maintained a Buy rating and a USD 457 price target for Amgen in a report released on November 19, according to Markets Insider. The call adds to a mixed analyst picture, with Barclays maintaining a Hold rating on November 16.
Amgen develops and delivers human therapeutics worldwide. Its newer growth portfolio includes Repatha, UPLIZNA and IMDELLTRA, while established products face pressure from biosimilar competition. Investors are weighing the pace of that product shift against the company's long-term pipeline, including its obesity candidate MariTide.
The broader market backdrop is tracked through the S&P 500.
